- Home
- TSSI vs KROS Comparison
TSSI vs KROS Comparison
Compare TSSI & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSSI
- KROS
- Stock Information
- Founded
- TSSI 2004
- KROS 2015
- Country
- TSSI United States
- KROS United States
- Employees
- TSSI N/A
- KROS N/A
- Industry
- TSSI Professional Services
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- TSSI Consumer Discretionary
- KROS Health Care
- Exchange
- TSSI Nasdaq
- KROS Nasdaq
- Market Cap
- TSSI 677.8M
- KROS 565.0M
- IPO Year
- TSSI N/A
- KROS 2020
- Fundamental
- Price
- TSSI $15.40
- KROS $15.56
- Analyst Decision
- TSSI
- KROS Buy
- Analyst Count
- TSSI 0
- KROS 14
- Target Price
- TSSI N/A
- KROS $20.56
- AVG Volume (30 Days)
- TSSI 3.5M
- KROS 474.1K
- Earning Date
- TSSI 08-06-2025
- KROS 08-06-2025
- Dividend Yield
- TSSI N/A
- KROS N/A
- EPS Growth
- TSSI 311.74
- KROS N/A
- EPS
- TSSI 0.34
- KROS 0.47
- Revenue
- TSSI $263,021,000.00
- KROS $232,844,000.00
- Revenue This Year
- TSSI N/A
- KROS $5,579.44
- Revenue Next Year
- TSSI N/A
- KROS N/A
- P/E Ratio
- TSSI $43.93
- KROS $32.60
- Revenue Growth
- TSSI 328.79
- KROS 85820.30
- 52 Week Low
- TSSI $4.13
- KROS $9.12
- 52 Week High
- TSSI $31.94
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- TSSI 33.85
- KROS 66.70
- Support Level
- TSSI $13.88
- KROS $14.04
- Resistance Level
- TSSI $15.63
- KROS $15.39
- Average True Range (ATR)
- TSSI 1.96
- KROS 0.60
- MACD
- TSSI -0.80
- KROS 0.13
- Stochastic Oscillator
- TSSI 8.52
- KROS 90.68
About TSSI TSS Inc. Common Stock
TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.